An HIVdrug should be tested to see if it would act as aneffective prophylactic for people who are HIV negative but are at high risk of contracting the infection, according to a group of experts.
After reviewing the possible candidates that could act as pre-exposure prophylaxis known as PREP the Dutch team found thatlamivudine (3TC) would work the best against the immunodeficiency virus.
The authors say: '3TC would make an interesting pre-exposure prophylactic drug given its relative safety, ease of use, mode of action and pharmacology, antiviral profile, and cost-effectiveness.?
However they are unsure if the drug would be most effective as monotherapy or in combination and war that it may be necessary to monitor the drug?s impact on chronic hepatitis B infection due to problems with resistant strains.
Public Library of Science Medicine(2006) 3:e454